Date: Dec. 15 (Tue.) 11:00 ~ 13:00 (KST)
Participation: Both Off-line and On-line
Off-line Venue – Grand Hyatt Hotel, Seoul, Korea
Hosts: KOFST, KSEA
Covid-19 and the Future of Global Cooperation and Science (Vaccine) Diplomacy
at Grand Hyatt, Seoul Meeting Room: Namsan III
Seunghwan (Swan) Kim
President of Korea Science Diplomacy Club
Former President of KSEA, USA
Recently, science and diplomacy are becoming increasingly crucial in tackling with complex international relations and addressing global challenges such as pandemics and other types of natural/man-made catastrophes. In the aftermaths of recent COVID-19 pandemic outbreak, in particular, vaccine diplomacy has been regarded as a critical element in global collaborations for overcoming the current pandemic and preparing us for other unforeseen challenges in the future.
The forum will focus on COVID-19 responses of South Korea, US and the world, and lessons learned from them to prepare the whole human race with the help of scientific research, technological innovations and tools of diplomacy. It will also serve as an opportunity for us to think about what the organization’s like KSEA, KOFST, and the science & public health communities, in general, can do to leverage their expertise for global integrative efforts such as vaccine diplomacy.
|Time (KST)||Titles and Speakers|
|11:00 AM||Opening Remarks Presidents of KOFST/KSEA, Chairs|
|11:10 AM||Keynote Speech|
Sir. Peter Gluckman (Chair, INGSA/President-Elect, ISC, Auckland, New Zealand)
Covid-19 and the Future of Global Cooperation and Science Diplomacy
|11:20 AM||Presentations |
Eric Goosby (Professor of Medicine, UCSF/Member of U.S. President-Elect Biden COVID-19 Advisory Board)
Roles of International Organizations on COVID-19 and of Science Community for Future
Youngmee Jee (Special Advisor to the Prime Minister in Health/Special Representative for Health Diplomacy, Korea Foundation, Korea)
Lessons learnt from Responses to the COVID-19 Outbreak and Way Forward
|12:00 PM||Round Table Panels|
Michael Reid (UCSF, USA),
Keeyong Chung (MOFA, Korea),
Hee Kwon Jung (MSIT, Korea)
Sir Peter Gluckman,
Distinguished Professor, University of Auckland
Director – Koi Tū: The Centre for Informed Futures,
Chair – International Network for Government Science Advice
President-Elect – International Science Council
Science diplomacy, Covid and the role of international science organisations
Professor Sir Peter Gluckman ONZ FRS is the founding chair of the International Network for Government Science Advice (INGSA), President-elect of the International Science Council, and was the first Chief Science Advisor to the Prime Minister of New Zealand. He was formerly Science Envoy, Chair of the APEC Chief Science Advisors and Equivalents group, and coordinator of the secretariat for the Small Advanced Economies Initiative.
Peter has written and spoken extensively on science-policy and science-diplomacy and sciencesociety interactions. He is Director of the newly established Koi Tū: Centre for Informed Futures, a research centre and think-tank at the University of Auckland. He trained as a pediatric and biomedical scientist and holds a Distinguished University Professorship at the Liggins Institute of the University of Auckland. He has published over 700 scientific papers and several technical and popular science books. He has received the highest scientific (Rutherford Medal) and civilian (Order of New Zealand) honours in NZ, and numerous international scientific awards. In 2016 he received the AAAS award in Science Diplomacy. He is a Fellow of the Royal Society of London, a member of the National Academy of edicine (USA) and a Fellow of the Academy of Medical Sciences (UK).
Eric Goosby, M.D., Professor of Medicine, Director, Center for
Global Health Delivery, Diplomacy and Economics
Institute for Global Health Sciences
University of California, San Francisco
Former UN Secretary-General’s Special Envoy
Eric Goosby is a Distinguished Professor of Medicine and Director of the Center for Global Health Delivery, Diplomacy and Economics, Institute for Global Health Sciences, at the University of California, San Francisco. He has been on the faculty at UCSF since the 1980s. He currently a member of the Biden Covid-19 Advisory Board and serves on the San Francisco Dept. of Public Health, Policy Group for the COVID-19 Response. In January 2015, Eric was appointed by UN Secretary-General Ban Ki-moon to be the UN Special Envoy on Tuberculosis (TB), and served in this capacity to 2019. As Special Envoy, he was central in the planning and implementation of the UN General Assembly High Level Meeting on TB in September 2018, and was lead Editor on the Lancet Commission on TB that outlined a global response to contain TB and send a message to world leaders that more resources are needed to make the world free from TB.
From 2009-2013, he served in the Obama Administration as Ambassador-at-Large and U.S. Global AIDS Coordinator, Assistant Secretary of State, overseeing the implementation of the President’s Emergency Plan for AIDS Relief (PEPFAR), and also founded and led the State Department’s Office of Global Health Diplomacy. As CEO and Chief Medical Officer of Pangaea Global AIDS Foundation, 2001-2009, he played a key role in the development and implementation of HIV/AIDS national treatment scale-up plans in South Africa, Rwanda, China and Ukraine. During the Clinton Administration,(1992-2000) Dr. Goosby was Director of the Ryan White Care
Act (brought treatment and enabling services to indigent AIDS patients in 52 US cities) at the U.S. Department of Health and Human Services (HHS), and later, served as Deputy Director of the White House National AIDS Policy Office and Director of the Office of HIV/AIDS Policy at HHS
where he created and chaired the Guidelines for Antiretroviral Therapy for Adults, Adolesecnets, and Pregnant Women.
Dr. Goosby is a member of the National Academy of Medicine and the Council on Foreign Relations. He is Board Chair of the International AIDS Vaccine Initiative, and is a member of the Advisory Board to the Director of NIH, Fogarty International NIH, the Clinton Floundation, Elton John Foundation and on Advisory/Guideline Boards for UNAIDS, WHO TB office and WHO HIV office. He remains active as an advisor to the UK Antimicrobial Resistance Initiative and to numerous Government Ministries of Health and Schools of Public Health in Sub Saharan Africa, Southeast Asia and Eastern Europe.
Youngmee Jee, (MD, PhD), Special Representative
for Health Diplomacy
Korea Foundation Visiting Professor,
Graduate School of Public Administration,
Seoul National University, Korea
Dr. Youngmee Jee is Special Representative for Health Diplomacy, Korea Foundation and a Visiting Professor at the Graduate School of Public Administration, Seoul National University. Recently, Dr. Jee was appointed as Special Advisor to the Prime Minister in Health. She has broad experience in collaborating with WHO and international public health partners. Currently, Dr. Jee is a member of the WHO International Health Regulation Emergency Committee on COVID-19 and of the WHO Scientific Advisory Group for the Blueprint on Research and Development Preparedness for Epidemics. From 2014 to 2019, she served as Director-General of the Center for Infectious Disease Research of the Korea Centers for Disease Control. Prior to this appointment, Dr. Jee worked for the Expanded Programme on Immunization in the WHO Western Pacific Region as a Scientist and Regional Coordinator during 2007-2014. She received a President Medal of Distinguished Service in 2017. She also served as a member of the Board of Trustees of the International Vaccine Institute (2016-2019) and President of the Korean Society of Infectious Diseases (2018-2019). She received her M.D. from Seoul National University Medical School (1986), a Diploma in Medical Microbiology (1988) and her Ph.D. in Virology from the University of London (1997).
Jerome H. Kim, Director
General International Vaccine Institute
Jerome Kim, M.D., is the Director General of the International Vaccine Institute (IVI) and an international expert on the evaluation and development of vaccines. His depth and breadth of scientific experience span basic research through advanced clinical development. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease. IVI’s typhoid conjugate vaccine, tech-transferred to SK bioscience and PT Bio Farma, is completing Phase III testing. IVI is working on several different vaccines against COVID-19, including the clinical testing of Inovio’s DNA vaccine at Seoul National University Hospital and Genexine’s COVID-19
vaccine at Severance Hospital. Dr. Kim was Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis, in the U.S. Military HIV Research Program (MHRP) and also served as the Project Manager for
the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Materiel Development Activity, Fort Detrick, MD. He led the Army’s Phase III HIV vaccine trial (RV144) which was the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination.
Dr. Kim has authored over 250 publications and received the John Maher Award for Research Excellence from the Uniformed Services University of the Health Sciences in 2013 and the Department of the Army R&D Award for Technical Excellence (2013). Dr. Kim is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences and at Yonsei University Graduate School of Public Health and a Fellow of the American College of Physicians and the Infectious Diseases Society of America. He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology, and received his M.D. from Yale University School of Medicine.
Michael Reid, Assistant Professor
Division of HIV, ID and Global Medicine, UCSF
Mike Reid is an infectious disease physician at San Francisco General Hospital and the University of California, San Francisco (UCSF). He is also the Associate Director of the Center for Global Health Diplomacy, Delivery and Economics at UCSF. He completed medical school at Cambridge University and medical residency in London, England and New York, USA. He did his infectious disease fellowship at UCSF and holds a Master’s degree in public health from UC Berkeley.
Since the start of COVID-19 outbreak he has been seconded to San Francisco’s Department of Public Health, where he is involved with running the contact tracing program. Mike is also the Chief Medical Officer for California’s Contact tracing training academy and heads up UCSF’s
Pandemic Initiative for Equity and Action (UPIEA). Prior to joining UCSF, he spent five years working in PEPFAR funded programs in Africa and was the lead physician in the University of Pennsylvania’s Global Health program in Gaborone, Botswana for three years. Michael has published more than 60 peer-reviewed publications on topics related to improving TB and HIV
service delivery in low-income settings.
Keeyong Chung, Esq. Governance Director
Global Green Growth Institute (GGGI)
Mr. Keeyong Chung is the Director of Governance of the Global Green Growth Institute (GGGI), headquartered in Seoul, Korea which aims to promote green growth, a growth paradigm that is characterized by a balance of economic growth and environmental sustainability.
Prior to joining GGGI, Mr. Chung was (and still is) a career diplomat having served in the Korean Foreign Ministry (MOFA) since 1993. He was involved and led efforts by the Korean Government on a wide range of issues including the ROK-US alliance, international public law (including maritime delimitation and state responsibility), climate change, personnel laws & regulations, Korea-Japan bilateral issues. Mr. Chung holds a Bachelor of Law (LL.B.) degree from Seoul National University College of Law in Seoul, Korea and a Juris Doctor (JD) degree from University of Pennsylvania Law School in Philadelphia, the United States of America. He is a member of the New York state bar.